Monday, July 22, 2013

A Brain Wave Diagnostic Test for ADHD?

Last week there was a lot of media buzz about a new product that uses brain waves to help diagnose ADHD. While the FDA press release was very carefully worded, the media was not always so careful. Below is a guest blog by Martijn Arns, PhD, a biological psychologist and researcher affiliated with Utrecht University in the Netherlands, to give all our CHADD members more information about this assessment device. This statement has been approved and adopted by CHADD’s Professional Advisory Board, the group of leading researchers and clinicians who help CHADD stay grounded in the science. - Ruth Hughes, PhD

A comment on: FDA permits marketing of first brain wave test to help assess children and teens for ADHD

guest blog by Martijn Arns, PhD
Utrecht University, Department of Experimental Psychology, Utrecht, The Netherlands
Research Institute Brainclinics, Nijmegen, The Netherlands

 In July 2013, the US Food and Drug Administration issued a press release with the above title, which quickly became very popular and attracted worldwide coverage with sources referring to it as a first brain test to diagnose children with ADHD. The test is commercialized by NEBA. The brain wave test referred to by the FDA consists of an EEG test (a technique which measures the electrical activity of the brain) whereby specifically the theta and beta waves are quantified and expressed in a so-called Theta/Beta ratio. Indeed, this measure has often been reported in scientific literature to deviate in children with ADHD. However, a recent meta-analysis which included all literature published on this measure to date – including a study from authors affiliated with NEBA – concluded that Theta/Beta ratio is not a reliable diagnostic marker for ADHD.* In a minority of ADHD patients (~25-30%), this measure is consistently found to deviate; however, such a percentage is too low to be used as a standalone diagnostic test. 

According to the FDA release, this brain wave test is also not approved as a standalone diagnostic test, but rather: “When used as part of a complete medical and psychological examination, the device can help confirm an ADHD diagnosis or a clinician’s decision that further diagnostic testing should focus on ADHD or other medical or behavioral conditions….” Therefore, this new device can simply be seen as one test in the whole spectrum of tests already used by clinicians to come to a diagnosis, similar to neuropsychological tests, IQ tests, ADHD rating scales, etc. This EEG test is not intended as a standalone diagnostic test.

Finally, also note that the FDA does not decide or rule on which treatments and tests are evidence-based or not. As stated in the title of their news release above, the FDA “permits marketing” of the device, and this decision is based on data submitted by the manufacturer that the device is safe to use. Scientific research and professional associations such as the American Psychological Association have guidelines to evaluate which tests and treatments can be considered evidence-based, and the EEG Theta/Beta measure is not recommended for making a diagnosis of ADHD.

*Arns, M., Conners, C. K., & Kraemer, H. C. (2012). A decade of EEG theta/beta ratio research in ADHD: A meta-analysis. Journal of Attention Disorders. doi:10.1177/1087054712460087

Monday, July 1, 2013

Drug Shortage Appears to be Growing

by Ruth Hughes, PhD

In just the few short weeks since my last blog, we have seen the shifting demand for methylphenidate generic products (Ritalin) grow from a shortage in two companies to six companies today. Pharmacists are finding it harder to order and it is taking longer to fill orders. The number of complaints coming to CHADD and to the American Academy of Child and Adolescent Psychiatry is also growing.

But most telling are the early responses to our survey asking patients, parents, and physicians to tell us if they are experiencing shortage problems in their area. Forty-four percent of the respondents are experiencing problems getting prescriptions filled for generic versions of Ritalin or other stimulant medications.

But we still need your help to define the scope of the shortage. We need to increase the overall number of respondents before taking this information to the federal government. Please fill out this short survey immediately and tell us about your experience. If you are a parent, please answer the patient questions. We need to hear from you even if you are having no problems, so we can gauge how serious any growing shortage might be. The survey will only take a few minutes to fill out and can help us ensure that there is an adequate supply of stimulant medication available.

CHADD and AACAP are poised to take action. Due to our concerns on this issue in 2012, the FDASIA law now contains a mechanism for addressing shortages that of medications that come under the purview of the Drug Enforcement Agency. The Secretary of Health and Human Services (FDA’s mother agency) can request the Attorney General of the Justice Department (DEA’s mother agency) to consider what actions the DEA should take to address the shortage and respond in 30 days. We already have a meeting scheduled with the FDA and will be asking for a meeting with Secretary Sebelius once we have a large enough response rate to the survey.

In the meantime, what can you do? You may have to call several pharmacies to find one in your area that has medication available. Report your shortage to the Food and Drug Administration by emailing with the specific name of the medication, the dosage and where you are located. And most importantly, please click HERE to complete this short survey by July 8. We will keep you updated on the scope of the shortage and our actions to address it.

Ruth Hughes, PhD, is CEO of CHADD.

Monday, June 10, 2013

Another Drug Shortage? Help Us Find Out!

by Ruth Hughes, PhD

Your help is needed to prevent another medication shortage. Recently, CHADD has been getting complaints from people experiencing difficulty in getting generic versions of methylphenidate (Ritalin). We want to be very sure to identify any drug shortage before it gets as serious as the problems we had in 2011 and 2012. We do know that two pharmaceutical companies (Mallinckrodt and Shionogi) have reported shortages to the Food and Drug Administration for versions of methylphenidate.

Tell us about your experience by answering a small number of questions in our drug shortage survey. We need to hear from you even if you are having no problems, so we can gauge how serious any growing shortage might be. The survey will only take a few minutes to fill out and can help us ensure that there is an adequate supply of stimulant medication available.

Once again CHADD and the American Academy of Child and Adolescent Psychiatry are working together to address this problem. If the survey results indicate we do have a shortage, we will approach the Secretary of Health and Human Services to ask the Drug Enforcement Agency to address this issue immediately. But your input is absolutely needed if we are to identify the scope of the problems.

Please click HERE to complete this short survey by June 12.  We will share the results with you at the end of the month.
Thank you for your feedback.

Ruth Hughes, PhD, is CEO of CHADD.

Friday, May 3, 2013

College Health Centers and ADHD

by Ruth Hughes, PhD

This week we have seen yet another story from New York Times journalist Alan Schwarz about ADHD and stimulant abuse linked with a story of suicide. Like many of the recent media articles on this serious issue, there is a more complex and I think more compelling story. Unfortunately, too many readers, clinicians, and institutions are ending up fearful of treatment for legitimately diagnosed ADHD while the issue of reducing stimulant abuse and diagnosing ADHD accurately often goes by the wayside.
While stimulant abuse is a very serious and out-of-control problem, the consistent link to suicide in many of these stories is highly misleading. When there is suicidal behavior there are always serious mental health problems and often substance abuse as well. Appropriate use of stimulants is not causally related to suicide. But reading the spate of media on this topic, you would easily be convinced that they are related. Creating an atmosphere of fear does not help us to rationally and effectively address the problem of stimulant abuse.

I was very dismayed at the description of college health centers that have stopped diagnosing and treating ADHD because it takes too much time to do it right. Do we stop diagnosing cancer, depression, appendicitis, or any other medical problem because it takes too much time? Proper and thorough evaluation combined with multimodal treatment within a university setting is one of the important things that a university can do to control stimulant abuse on campus. It seems to me that some of the knee-jerk reaction is more out of concern about liability and reputation, than about good medical treatment.

When working on this story, Alan Schwarz contacted CHADD and asked for our take on this issue. I would like to share with all of you the written comments I gave to the New York Times in their entirety.
[Text of comments to NYT]

At CHADD we are very concerned about stimulant abuse for a series of reasons. First, no one should be using any prescription drug that has not been prescribed for them. There are the consequences of side effects, drug interactions and other problems that may place a person at risk. If an individual feels it’s okay to use a stimulant, it is too easy to then take an opiate that has not been prescribed and is then entering even more dangerous practices. Prescription abuse is never acceptable.

Second, stimulant abuse and the emotional reaction that it have engendered has many adverse consequences for people who need stimulant treatment for ADHD. It makes it more unacceptable to seek diagnosis and treatment and creates a culture of fear and stigma. Many of our members reported during the drug shortage last year that they were treated like drug addicts when they had to go to more than one pharmacy to find who had stimulant medications.

CHADD strongly advocates for a good diagnostic and evaluation process which entails spending extensive time with a patient, getting an in depth history of the patient and the family, asking for reports from family members, teachers, or employers, as well as observation of the patient directly and utilization of symptom checklist. This cannot be done in ten minutes. If a physician is unable or unwilling to do an in depth evaluation, then a patient should be referred to a specialist who will do this level of evaluation.

Looking at the information you provided about college response to this issue, it seems to me a very mixed group of interventions. Here are the questions I would urge a college to consider when making policy about stimulant abuse:
  1. Any policies related to stimulant abuse should be consistent for all controlled medications. So if a college health center asks a student to attend sign an agreement about abuse, it should also be used for a student prescribed a pain killer given for a sports injury. 
  2. Are the actions proposed going to both help the patient as well as reduce the possibility of stimulant misuse?
  3. Are there other disorders that have the same or higher level of risks, and are those disorders being treated in a similar fashion?
  4. And are the policies in the best interest of the student presenting with the symptoms?
  5. What other actions need to be taken to reduce stimulant misuse on campus?
Requiring students to sign a release to allow the physician to contact parents for a history is good medical practice and should always be happening. A proper evaluation for ADHD should ALWAYS include the reports of other key informants, a lifetime history of either treatment for ADHD or the symptoms of ADHD and an in-depth evaluation that cannot be done in ten minutes. For the same reason CHADD understands the requirement of monthly counseling sessions. This is always a component of good, multimodal treatment for ADHD. I hope these treatment sessions are designed to help the student with the challenges of college life and ADHD, and are not just centered on stimulant misuse.

I am very concerned about any university health center that refuses to diagnose students with ADHD or does not allow a clinician to prescribe stimulants. It appears to me that these schools are more concerned about liability issues than good medical treatment or controlling abuse of stimulants. And I would also suggest that this deviates significantly from the established standards of care and practice guidelines for physicians dealing with ADHD. It is also discriminatory if the health center does not do the same for all controlled medications. The abuse of pain medications is a much larger problem with much more serious consequences. Are they also refusing to treat pain related to injury, treatment, or illness? If a university is very concerned about stimulant abuse, I would think the worst thing they could do is to relinquish this responsibility to unknown community practitioners. Nonprescribed use of stimulant medications on campus is a serious problem that can’t just be punted to someone else outside the school grounds.

CHADD is deeply concerned about the misuse of stimulants. We work with our members and young adults to learn how to more safely manage the medications, and how to deal with peer pressure to share. We are also concerned that legitimate diagnosis and treatment of ADHD in young people in particular is endangered, because of concerns about stimulant misuse.

[End of comments to NYT]

I share my written comments to the New York Times here primarily to inform our members about CHADD’s take on the issue of health care on college campuses as well as to provide insight into CHADD’s outreach efforts with the media.

CHADD will continue to provide evidence-based information about ADHD. We will strive to increase understanding of the complex issues of ADHD diagnosis and treatment. The press doesn’t always get it right, and in the case of a medical condition like ADHD, may do unintentional harm by adding to the stigma and fear associated with the disorder or the treatment. For all of you who have ADHD or have a loved one with ADHD, it is imperative that we set the record straight, and help our communities understand that ADHD is a real neurological disorder that can be accurately diagnosed and effectively treated.

Ruth Hughes, PhD, is CEO of CHADD.

Monday, February 25, 2013

Preventing Harm on All Fronts

Guest blog by Ann Abramowitz, PhD, and Theresa E. Laurie Maitland, PhD

The tragic story of Richard Fee, as told by New York Times reporter Alan Schwarz, is one of the most disturbing pieces either of us has ever read. As the chair and co-chair, respectively, of CHADD’s Professional Advisory Board, we decided to share our own thoughts with the hope that we may enrich the discussion and help to prevent similar tragedies in the future.

First, a word about CHADD’s PAB: We are a group of professionals, mostly in academic settings, who also work clinically with children, teens, and adults with ADHD. Our task is to provide CHADD with scientific guidance, so that the information provided to the public is scientifically accurate and up-to-date. One of us is a clinical psychologist and full-time faculty member at a university, involved in the training of both clinical psychologists and child and adolescent psychiatrists, and also with a clinical practice. The other is an ADHD/LD specialist and coach who coordinates a university program for college students with ADHD and/or LD. The article describing Richard Fee’s situation left us with a number of questions and reactions.

The first question we had was whether Richard had ADHD. The article strongly suggests that he did not, based on his parents’ conviction that he had not had symptoms until after college, and we have to speculate whether the difficulty concentrating that arose at that time was more likely attributable to some other disorder. One of us is a psychologist, and the other is an educator. We are not physicians and cannot prescribe medication, but all professionals who work with people with ADHD should have knowledge of all evidence-based treatments for ADHD, including medication. It is well known that very rarely psychotic symptoms are triggered by stimulant medication, and it is also well known that stimulant medication must be avoided in individuals who present with psychotic symptoms. Careful assessment and diagnosis are crucial.

As Dr. Keith Conners explains in the New York Times article, the practice standards for the diagnosis of ADHD in adults call for corroborative evidence, and go far beyond the completion of self-report symptom checklists. If a clinician (psychiatrist, psychologist, or other health professional) relies only on self-report, the likelihood of misdiagnosis is significant. One reason is that it would be relatively easy to report having the symptoms of ADHD in order to obtain medication; a second reason is that the individual may have serious psychopathology, yet might lack insight into that fact. But even corroborative reports of symptoms by others are not sufficient evidence upon which to base a diagnosis; the history given by the parents, provided in school records, and the completion of psychological testing all enable the clinician to achieve the essential understanding for making an accurate diagnosis. ADHD does not first appear in adulthood. Misdiagnosing another mental disorder as ADHD can be catastrophic, particularly if psychosis is involved.

How can it be that a careful history may not always be done? We don’t know what happened in Richard’s case, but if the diagnosis was made based only on self-report this would be completely inconsistent with practice standards. Unfortunately, there may still be professionals who diagnose adults, including college students, without completing a careful history and conducting a comprehensive assessment to rule out other co-existing conditions. As the tragic story of Richard Fee demonstrates, this must change.

Let’s speculate that Richard refused to allow his parents to be involved. Perhaps he also refused to allow current corroborative report, such as instructors, roommates, or employers. How does a clinician conducting an evaluation of a young adult obtain the background information and current corroborative information while respecting his or her wishes and privacy? The answer, while never simple, must rest on this simple truth: Self-report of symptoms cannot be considered sufficient. By requiring new patients to provide corroborative information, clinicians may reduce the possibility of diagnosing individuals who are seeking to obtain stimulants or who may have other serious conditions. Our experiences working extensively with young adults, including many college students, suggest that it is important to help them understand why this is needed. We believe that working together with a caring clinician, those with ADHD find ways to obtain the information that is needed to reach a careful and accurate diagnosis. This often happens as trust builds, and as the young adult recognizes, and is grateful for, how much care and time are going into the evaluation.

A final, wrenching question nags at the reader: How can it be that the parents, describing their son’s severe psychopathology and Adderall abuse to the prescribing psychiatrists, went unheard? Even acknowledging the requirements of HIPAA, we cannot find an answer. The lack of involvement of families in the treatment of mental illness is a serious problem that professionals must grapple with, not just those specializing in ADHD. When working with young adults who are still dependent upon their parents for their livelihood and care, professionals need to create respectful methods for protecting the young adult’s confidentiality while designing ways to integrate in the input of family members and significant others. Given the potential lack of self-awareness in individuals with ADHD, it is essential to elicit feedback from others who may have more accurate observations and may also need help in learning about their loved one’s condition. Hopefully, we will learn from this tragedy as well as others that even given the boundaries of HIPAA there are ways to obtain information that is crucial for accurate diagnosis and appropriate treatment, and that harm can be done when this does not occur.

Yet, in our work with college students, we also cannot deny that stimulant abuse/misuse is a real problem on college campuses. This tragic story brings this situation to light. Hopefully, this article will be a wake-up call for professionals who are not following the standards for diagnosis of young adults with ADHD. The pressures for success and competition at college may drive some to seek medication to quickly improve their performance rather than choose the much slower process of changing their behavior and study habits.

The reality of stimulant abuse/misuse and the media’s continual focus on situations like Richard Fee’s can spawn other tragedies. The self-perception of many young adults who have or suspect they have ADHD can be adversely impacted. Painful stories like these can add to the misunderstanding and misinformation on ADHD that makes many of them reluctant to use medication or seek help. Although there are obviously young adults who feign ADHD symptoms just to get the medication, people working in campus learning centers may not ever meet them. Since these programs do not offer a quick fix, but offer ongoing help in learning to accept ADHD and learning how to live life productively with it, professionals tend to meet students who wait until they have “hit bottom” and are humiliated, devastated, and feeling as if they have “lost their smarts.” At this low point they are finally willing to find more effective ways of living with the chaos and challenges created by ADHD.

Many times young adults are not seeking help or not using prescribed medication because they report wanting to be “normal” and view help seeking negatively. They have adopted the beliefs from society that they “should” be able to control their attention on their own and that ADHD is not real. Yet they discover, with great trepidation, that they cannot seem to control their attention or behavior. When talking about the issue of students who may be feigning ADHD just to get medication, one student said, “I just don’t get it, who would want to fake having a life like mine?” Although stories abound about students whose lives were dramatically improved by Adderall or other medications, these are not typically covered in the media because they lack the sensationalism that the tragic stories have. There are thousands of young adults who truly have ADHD and use medication responsibly, and the media focus on those who were incorrectly diagnosed or treated can tragically undermine their confidence and hinder their decision to seek help.

Ann Abramowitz, PhD, is a professor in the department of psychology at Emory University and supervises residents in the division of child and adolescent psychiatry at the university's medical school. Theresa E. Laurie Maitland, PhD, is the coordinator of the Academic Success Program for Students with LD and ADHD at the University of North Carolina at Chapel Hill.
Visit CHADD's web page on Medication Abuse and Diversion.

Monday, February 4, 2013

Substance Abuse, ADHD, and Medications: The Real Issues

by Ruth Hughes, PhD

The story of Richard Fee, as reported in the New York Times on Sunday, February 3, is as heart-wrenching as it is atypical in ADHD treatment. This was not a story about ADHD or about Adderall, but rather about substance abuse and our highly stressed and fragmented mental health system. As the mother of a young adult in college, my heart went out to this young man’s parents, who tried so valiantly to stop the downward spiral of his addiction.

Anyone who works in mental health or who has attempted to use mental health services can attest to the fact that there are multiple barriers to receiving effective treatment. There are simply not enough providers to address the many patients needing services in a timely way. The HIPAA privacy laws make it impossible for clinicians to speak with family members or with other providers, especially when a young adult refuses to sign a release of information request. Payment rates through insurance are so low for mental health services that many providers will no longer participate. And no one is willing to pay for the time needed for the outreach and collaboration that is so necessary for proper diagnosis and treatment. When the symptoms of mental illness (or addiction) interfere with good judgment or accurate reporting by the patient, the effects of these problems are multiplied many times over.

This is not an excuse for the careful evaluation and collaboration that appeared to be missing in the treatment of Richard Fee, but rather a statement of the disarray of our health care system. CHADD, along with many other mental health advocacy organizations, continues to fight for a better health care system, for parity in mental health services, and for better coverage of treatment for all mental health disorders. And we work with our professional counterparts to ensure training of mental health professionals in the diagnosis and treatment of ADHD is easily available and of high quality.

Unfortunately, the scary tone of this article misrepresents the danger of stimulant medications. Stimulant medications that are taken as prescribed are highly unlikely to lead to addiction. In fact, the director of the National Institute on Drug Abuse, Dr. Nora Volkow, states, “Methylphenidate treatment for children with ADHD does not increase their risk for later substance abuse,” in an article summarizing NIDA research on stimulants and abuse.

It is important to separate several related but different issues on substance abuse, ADHD, and medications:
  • Stimulant medications are often an integral part of treatment for ADHD, but the most effective treatment will include parent/family training, behavioral interventions, and school/work support as well as medications. Stimulants can help a person’s brain work more efficiently, but medication does not teach coping skills.

  • Anyone with ADHD has a higher risk of substance abuse. This is not because of the medication, but because the disorder itself is characterized by impulsivity and poor recognition of consequences. Few people with ADHD choose stimulants as the substance of abuse. Alcohol, cigarettes, and drugs will be more of a temptation for a person with ADHD. We must help anyone with ADHD be forewarned that there is a higher risk of substance abuse and we must be vigilant for early warning signs.

  • Misuse of stimulant medication as a study aid is unfortunately a regular occurrence on college campuses. CHADD is strongly opposed to the diversion of stimulants, which undermines the legitimate use of stimulants for the treatment of ADHD. We regularly warn parents and young people of both the criminal and health outcomes associated with diversion. The federal government’s most recent survey of substance abuse (page 15) indicated that misuse of stimulant medication is present in about 0.4% of the population, or 1.1 million people over the age of 12. Although the incidence of misuse has declined from 0.6% in 2003, it remains a serious problem that CHADD is very concerned about.

  • Misuse is not the same as addiction. Stimulant medications may become addictive when taken in very large dosages or when injected intravenously. Few addicts choose stimulants as their drug of choice. As the New York Times article reported, “Very few people who misuse stimulants devolve into psychotic or suicidal addicts.” That said, one person who becomes addicted is one too many. It is crucial that our health care systems do everything possible to prevent the misuse or addiction of any prescription drugs.

One final comment. A meeting of a local CHADD group was referenced at the end of the article. Unfortunately, comments made by CHADD board member Jeffrey Katz, PhD, were selectively reported, and crucial information that both CHADD and Dr. Katz always include was not reported. When asked about the safety of stimulant medications, Dr. Katz reminded the audience that he was not a physician and that an individual’s response to medication can vary dramatically. At all times, a person thinking about or taking any medication for ADHD should work closely with his or her physician. In general, the potential side effects of stimulant medications when taken as prescribed are relatively mild and can be safely managed.

The science of ADHD, investigating the causes, diagnosis, and treatment, has improved dramatically over the past decade. It is absolutely crucial that our clinical practice and our public policy be based on the most recent and most sound facts. It is for this reason that we need to continue and/or increase funding support for better research in mental health and improved treatment in our health care systems. CHADD is committed to ensuring that evidence-based information from research is at the forefront of any discussions about ADHD treatment.

CHADD will continue to fight for better health care services, better training of providers, and the elimination of diversion of prescription medications. We want to be certain that all our members and the general public have accurate, science-based information about ADHD and any of the related disorders that often accompany a diagnosis of ADHD.

Visit CHADD's web page on Medication Abuse and Diversion.

Ruth Hughes, PhD, is CEO of CHADD.